Zenapax daclizumab: Phase III; marketed to prevent renal transplant rejection

By WIR Staff | Mar 6, 2000 | 8:00 AM GMT

Researchers published in The New England Journal of Medicine results of a

Read the full 125 word article

How to gain access

Continue reading with a
two-week free trial.